-5%
Emixef is an orally administered, third-generation cephalosporin antibiotic with strong in-vitro bactericidal activity against a broad range of Gram-positive and Gram-negative organisms. It is indicated for the treatment of acute infections caused by susceptible pathogens, particularly where resistance to commonly used antibiotics is suspected or where treatment failure may pose significant risk.
Cefixime-
Upper Respiratory Tract Infections (URTI)
- Otitis media
- Other URTIs caused by organisms resistant to standard antibiotics
Lower Respiratory Tract Infections
- Acute and chronic bronchitis
Urinary Tract Infections
- Cystitis
- Cystourethritis
- Pyelonephritis
- Clinical efficacy has been demonstrated against commonly encountered pathogens, including:
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Escherichia coli
- Proteus mirabilis
- Klebsiella species
- Haemophilus influenzae (β-lactamase positive and negative)
- Moraxella catarrhalis (β-lactamase positive and negative)
- Enterobacter species
- Emixef remains highly stable in the presence of β-lactamase enzymes.
Cefixime is a third-generation semi-synthetic cephalosporin intended for oral use. It exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to bacterial death. Due to its stability against β-lactamase enzymes, many organisms resistant to penicillins and earlier cephalosporins remain susceptible to cefixime. Oral absorption is approximately 40–50%, and food intake does not significantly affect its bioavailability.